Unraveling the Biological Drivers of ME

ME is a deeply complex disease with many different causes and risk factors.

In over 30 years of global research into the disease, not a single replicable genetic finding had been reported until now.

We have for the first time identified some of the different genetic mechanisms causing ME/CFS and used this to stratify patients.

We’re currently replicating our results in a much larger, better characterized patient population, using thee DecodeME study data as part of the LOCOME (Long Covid and ME) grant supported by Innovate UK.

We're now conducting research to:

1. Validate simple saliva/blood genotyping tests for ME/CFS and long COVID
2. Identify actively protective biology that may prevent people getting ME or  help them to recover
3. Identify and validate drug repurposing candidates that may be able to treat ME patients

On this page, we've collated recent papers, posters, videos and blogs, about our ME/CFS and long COVID research.

Progress Summary	Poster
Beginning to Unravel the Biological Drivers of ME Overview of our recent ME/CFS and long Covid research and the clinical validation of new therapeutics and diagnostic tests.	Identifying Genetic Risk Factors for ME/CFS and Long COVID  Poster detailing our discovery of the first genetic associations, novel targets, actively protective biology, and diagnostics.

Papers
Genetic Risk Factors for ME/CFS Identified using Combinatorial Analysis	Genetic Risk Factors for Severe and Fatigue Dominant Long COVID and Commonalities with ME/CFS Identified by Combinatorial Analysis

Videos
Genomics and Genetic Susceptibilities of ME Presented at the NIH ME/CFS Research Roadmap Webinar 2024	Precision Medicine for Long COVID and ME/CFS Presented at the Unite to Fight ME Conference 2024

 

The Causal Biology of ME Presented at the Invest in ME Research Congress 2024

 

 

Recent News
PrecisionLife and Metrodora Institute share first insights with ME/CFS, Long COVID participants in MetX study	Precision Medicine Clinical Trials Lunched for ME/CFS and Long Covid to Accelerate Diagnosis and Treatment
PrecisionLife Project Awarded Innovate UK Grant to Improve Diagnosis and Treatment of ME/CFS and Long Covid

 

 

Blog
New Study Links 14 Genes to ME/CFS By Simon McGrath for the ME/CFS Rsearch Review

About PrecisionLife

PrecisionLife is a pioneering precision medicine company changing the way the world predicts, prevents, and treats complex, chronic diseases by finding better, more personalized diagnostic and treatment options for patients.

Our platform is unique in its ability to identify causal biology and link chronic disease patients to effective treatments via the molecular mechanism of their disease or drug response. These insights enable us to significantly improve probabilities of success across the biopharma and healthcare value chain.

We discover new subgroups of patients with mechanism-based patient stratification biomarkers, identify novel treatment opportunities for unmet medical needs, de-risk and accelerate clinical trials, find new applications for existing drug programs, and build highly predictive complementary diagnostics, personalized risk prediction and disease prevention tools.

We’re working in collaboration with some of the largest global biopharma companies and have a proven, responsive
and cost-effective way of contracting and working with our partners which recognizes, respects and complements their
existing team’s expertise and processes.

Contact us via the form below to find out more about partnering with PrecisionLife.